Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - irinotecan hydrochloride injection, usp is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity

Australija - anglų - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - irinotecan hydrochloride trihydrate, quantity: 500 mg - injection, concentrated - excipient ingredients: sorbitol; lactic acid; water for injections - irinotecan injection concentrate is indicated as a component of first-line therapy for patients with metastatic carcinoma of the colon or rectum. irinotecan injection concentrate is also indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial therapy.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

apotex corp. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - •irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. •irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. •irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal studies, intravenous administration of irinotecan to rats and rabbits during the period of organogenesis resulted in embryofetal mortality and teratogenicity in pregnant animals at exposures lower than the human exposure based on auc at the clinical dose of 125 mg/m2 (see data ). advise pregnant women of the potential risk to a fetus. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. animal data radioactivity related to 14 c-irinotecan crosses the placenta of rats following intravenous administration. intravenous administration of irinotecan to rats at a dose of 6 mg/kg/day (approximately 0.2 times the clinical exposure (auc) at the 125 mg/m2 dose based on exposure data from a separate rat study) during the period of organogenesis resulted in increased post-implantation loss and decreased numbers of live fetuses; at doses ≥ 1.2 mg/kg/day (approximately 0.03 times the clinical exposure (auc) at the 125 mg/m2 dose based on exposure data from a separate rat study) there were increases in a variety of external, visceral, and skeletal abnormalities. administration of irinotecan to pregnant rabbits at a dose of 6 mg/kg (approximately half of the clinical dose of 125 mg/m2 based on bsa) resulted in similar findings to those in rats, with increased post-implantation loss, decreased live fetuses, and increased external, visceral, and skeletal abnormalities. irinotecan administered to rat dams for the period following organogenesis through weaning at doses of 6 mg/kg/day caused decreased learning ability and decreased female body weights in the offspring. females advise female patients of reproductive potential to use effective contraception during treatment and for 6 months after the final dose of irinotecan hydrochloride injection [see use in specific populations (8.1) and nonclinical toxicology (13.1)]. males due to the potential for genotoxicity, advise male patients with female partners of reproductive potential to use condoms during treatment and for 3 months after the final dose of irinotecan hydrochloride injection [see nonclinical toxicology (13.1)]. females based on postmarketing reports, female fertility may be impaired by treatment with irinotecan hydrochloride injection. menstrual dysfunction has been reported following irinotecan hydrochloride injection administration. males based on findings from animal studies, male fertility may be impaired by treatment with irinotecan hydrochloride injection [see nonclinical toxicology (13.1)]. the effectiveness of irinotecan in pediatric patients has not been established. results from two open-label, single arm studies were evaluated. one hundred and seventy children with refractory solid tumors were enrolled in one phase 2 trial in which 50 mg/m2 of irinotecan was infused for 5 consecutive days every 3 weeks. grade 3-4 neutropenia was experienced by 54 (31.8%) patients. neutropenia was complicated by fever in 15 (8.8%) patients. grade 3-4 diarrhea was observed in 35 (20.6%) patients. this adverse event profile was comparable to that observed in adults. in the second phase 2 trial of 21 children with previously untreated rhabdomyosarcoma, 20 mg/m2 of irinotecan was infused for 5 consecutive days on weeks 0, 1, 3 and 4. this single agent therapy was followed by multimodal therapy. accrual to the single agent irinotecan phase was halted due to the high rate (28.6%) of progressive disease and the early deaths (14%). the adverse event profile was different in this study from that observed in adults; the most significant grade 3 or 4 adverse events were dehydration experienced by 6 patients (28.6%) associated with severe hypokalemia in 5 patients (23.8%) and hyponatremia in 3 patients (14.3%); in addition grade 3-4 infection was reported in 5 patients (23.8%) (across all courses of therapy and irrespective of causal relationship). pharmacokinetic parameters for irinotecan and sn-38 were determined in 2 pediatric solid-tumor trials at dose levels of 50 mg/m2 (60-min infusion, n=48) and 125 mg/m2 (90-min infusion, n=6). irinotecan clearance (mean ± s.d.) was 17.3 ± 6.7 l/h/m2 for the 50 mg/m2 dose and 16.2 ± 4.6 l/h/m2 for the 125 mg/m2 dose, which is comparable to that in adults. dose-normalized sn-38 auc values were comparable between adults and children. minimal accumulation of irinotecan and sn-38 was observed in children on daily dosing regimens [daily x 5 every 3 weeks or (daily x 5) x 2 weeks every 3 weeks]. patients greater than 65 years of age should be closely monitored because of a greater risk of early and late diarrhea in this population [ see clinical pharmacology (12.3) and adverse reactions (6.1) ] . the starting dose of irinotecan hydrochloride injection in patients 70 years and older for the once-every-3-week-dosage schedule should be 300 mg/m2 [ see clinical pharmacology (12.3) and dosage and administration (2) ] . the frequency of grade 3 and 4 late diarrhea by age was significantly greater in patients ≥65 years than in patients <65 years (40% [53/133] versus 23% [40/171]; p=0.002). in another study of 183 patients treated on the weekly schedule, the frequency of grade 3 or 4 late diarrhea in patients ≥65 years of age was 28.6% [26/91] and in patients <65 years of age was 23.9% [22/92]. the influence of renal impairment on the pharmacokinetics of irinotecan has not been evaluated. therefore, use caution in patients with impaired renal function. irinotecan is not recommended for use in patients on dialysis. irinotecan clearance is diminished in patients with hepatic impairment while exposure to the active metabolite sn-38 is increased relative to that in patients with normal hepatic function. the magnitude of these effects is proportional to the degree of liver impairment as measured by elevations in total bilirubin and transaminase concentrations. therefore, use caution when administering irinotecan hydrochloride injection to patients with hepatic impairment. the tolerability of irinotecan in patients with hepatic dysfunction (bilirubin greater than 2 mg/dl) has not been assessed sufficiently, and no recommendations for dosing can be made [ see dosage and administration (2.1), warnings and precautions (5.10) and clinical pharmacology (12.3) ] .

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

sagent pharmaceuticals - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - - irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarri

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

actavis pharma, inc. - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 20 mg in 1 ml - - irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summary based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarri

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - irinotecan hydrochloride (unii: 042laq1iis) (irinotecan - unii:7673326042) - irinotecan hydrochloride 40 mg in 2 ml - - irinotecan hydrochloride injection is indicated as a component of first-line therapy in combination with 5-fluorouracil (5-fu) and leucovorin (lv) for patients with metastatic carcinoma of the colon or rectum. - irinotecan hydrochloride injection is indicated for patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy. - irinotecan hydrochloride injection is contraindicated in patients with a known hypersensitivity to the drug or its excipients. risk summar y based on findings from animal studies and its mechanism of action, irinotecan hydrochloride injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)]. available postmarketing and published data reporting the use of irinotecan hydrochloride injection in pregnant women, are insufficient and confounded by the concomitant use of other cytotoxic drugs, to evaluate for any drug-associated risk for major birth defects, miscarr

Prancūzija - prancūzų - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

fresenius kabi france sa - irinotécan 17 - solution - 17,33 mg - pour 1 ml de solution > irinotécan 17,33 mg sous forme de : chlorhydrate d'irinotécan trihydraté 20 mg - cytotoxique inhibiteur de la topoisomérase i - irinotecan kabi est un médicament anticancéreux contenant comme substance active le chlorhydrate d’irinotécan trihydraté.le chlorhydrate d’irinotécan trihydraté interfère avec la croissance et la propagation des cellules cancéreuses dans l’organisme. irinotecan kabi est indiqué en association avec d’autres médicaments dans le traitement des patients présentant un cancer du côlon ou du rectum avancé ou métastasique.irinotecan kabi peut être utilisé seul, chez les patients atteints de cancer du côlon ou du rectum métastatique dont la maladie a récidivé ou progressé suite à un traitement initial à base de fluorouracile.

Prancūzija - prancūzų - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

hikma farmaceutica (portugal) sa - irinotécan 17 - solution - 17,33 mg - pour 1 ml de solution > irinotécan 17,33 mg sous forme de : chlorhydrate d'irinotécan trihydraté 20 mg - cytotoxique inhibiteur de la topoisomérase i - irinotecan hikma est un médicament anticancéreux contenant une substance active appelée chlorhydrate d’irinotécan trihydraté.le chlorhydrate d’irinotécan trihydraté interfère avec la croissance et la propagation des cellules cancéreuses dans l’organisme.irinotecan hikma est utilisé en association avec d’autres médicaments dans le traitement des patients présentant un cancer du côlon ou du rectum avancé ou métastatique..irinotecan hikma peut être utilisé seul chez les patients atteints de cancer du côlon ou du rectum métastatique dont la maladie a récidivé ou progressé suite à un traitement initial à base de 5‑ fluorouracile.

Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - irinotecano - concentrado para solução para perfusão - 100 mg/5 ml - irinotecano, cloridrato tri-hidratado 20 mg/ml - irinotecan - genérico - duração do tratamento: longa duração

Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

hikma farmacêutica (portugal), s.a. - irinotecano - concentrado para solução para perfusão - 300 mg/15 ml - irinotecano, cloridrato tri-hidratado 20 mg/ml - irinotecan - genérico - duração do tratamento: longa duração